AzTrials
AzTrials

RT-QuICNCT07498686

Plasma a-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Neurodegeneration Disease

An observational study of RT-QuIC, run by Xuanwu Hospital, Beijing at 2 sites in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Synuclein disease, also known as Synucleinopathies, is a general term for a class of degenerative diseases. It mainly includes Parkinson's disease (PD), Dementia with lewy bodies (DLB), Multiple system atrophy (MSA) and so on. Read more about this study

Who is it for?
Ages 18 to 95 yearsHealthy volunteers can take part
Conditions the study is for
RT-QuIC
How many people
458 participants
Where
2 sitesChina
Study dates
1 May 2023to 23 Dec 2026
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 95 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: Control,PD,MSA,PSP

Who may be able to join

  • Grouping criteria for PD patients: All PD patients who join the group need to meet the following conditions at the same time: The diagnosis of primary PD patients is based on the 2015 International Association for Movement Disorders (MDS) Parkinson's disease diagnosis standard, and all patients need to meet the clinical diagnosis or likely Parkinson's disease diagnosis criteria. Quasi; All patients come from the outpatient clinic of Xuanwu Hospital Affiliated to Capital Medical University, and the clinical evaluation and disease diagnosis are completed by a movement disorder specialist. This project is approved by the Ethics Committee of Xuanwu Hospital Affiliated to Capital Medical University. The subjects who participated in the study signed the informed consent form. Fully improve the information of PD patients and form an NSFC 2024 clinical information database. Establish an evaluation scale based on various indicators such as basic demographic data, general disease status and past history and exercise symptom evaluation, including Hoehn \& Yahr staging, unified Parkinson's disease assessment scale (MDS- UPDRS), concise mental state examination (MMSE) examination, Monte Lear scale (MOCA), rapid eye movement sleep behavior disorder Hong Kong questionnaire (RBDQ-HK), Hamilton depression scale (HAMD) and anxiety scale (HAMA), integrating a number of sports and non-sports indicators, comprehensively considering and evaluating the patient's condition, for the follow-up relevant Sexual analysis provides accurate and complete clinical information.MSA patients need to meet the MSA clinical diagnosis criteria updated in 2008 by the Europe Multiple System Atrophy Study Group (EMSA-SG). For DLB patients, use the 2017 standard for diagnosis and grouping.

Who cannot join

  • Patients with Parkinson's syndrome but not primary PD, patients with brain surgery/deep brain electrode stimulation, or patients diagnosed with dementia according to the Diagnostic and Statistical Manual of Mental Illness formulated by the American Association of Mental Illness. PD patients with mild cognitive dysfunction are not excluded.

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Weiwei YANG, Ph.D. contact

+86 010-83198271

yangww_2010@163.com

China2 sites, 1 recruiting
  • Xuanwu Hospital

    Beijing, Beijing Municipality, 100053

    Completed
  • Xuanwu Hospital

    Beijing, Beijing Municipality, 100053

    Weiwei YANG, +86 010-83198271, yangww_2010@163.com

    Recruiting

Other trials in China

About this study

Synuclein disease, also known as Synucleinopathies, is a general term for a class of degenerative diseases. It mainly includes Parkinson's disease (PD), Dementia with lewy bodies (DLB), Multiple system atrophy (MSA) and so on. The disease is characterized by the abnormal folding of alpha-synuclein (α-syn) in the peripheral and central nervous system, resulting in the production of lewy bodies, lewy neurites, neurons, and glial cytoplasmic inclusion bodies in neurons or glial cells. The intracellular location and accumulation pattern of α-syn vary in different synuclein diseases. There are overlapping conditions between synuclein diseases, which also makes the accuracy of clinical diagnosis of synuclein diseases very low. A definitive diagnosis can be made only after the patient has died and brain samples are evaluated using immunohistochemical staining. Therefore, in order to intervene and save synuclein disease in advance, it is necessary to develop more accurate and less invasive diagnostic methods.

Real-Time Quaking Induced Conversion (RT-QuIC) is a method for in vitro amplification of pathogenic protein seeds, which can enable seed proteins with in vitro amplification ability to transform substrates into misfolded seeds under specific conditions. RT-QuIC was originally used in the diagnosis of patients with prion protein. The technique can identify the prion protein in the misfolded form in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease with a specificity of 100% and a sensitivity of 95-98%, so it has been incorporated into the clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Studies have shown that pathogenic seeds extracted from patients' cerebrospinal fluid or other biological fluids or tissues are incubated with recombinant protein substrates, and the use of intermittent shaking to promote the interaction between the seed and substrate can force the substrate to transform into pathogenic protein seeds. The RT-QuIC reaction process is monitored in real time by a detector inside the machine for thioflavin, a fluorescent dye that fluoresces when bound to the beta lamellar layer, which is also typical of amyloid fibrils. Studies have shown that testing patients' cerebrospinal fluid with RT-QuIC can accurately distinguish lewy body dementia from non-Parkinson's dementia In this study, RT-QuIC technique was used to amplify the misfolded α-syn in clinical samples to explore the differences in protein characteristics among synuclein diseases, and to try to diagnose synuclein diseases by this method. Firstly, clinical cases of synucleoprotein disease were enrolled, and plasma of 100 control subjects, 221 cases of PD patients and 127 cases MSA patients, 10 cases of PSP patients, were established. Using RT-QuIC technology, we used aSyn (successfully prepared in our laboratory) to amplify the plasma of normal subjects and Synucleinopathies patients. It was found that the maximum fluorescence intensity (extreme value), peak time, K/2 (slope at extreme value/2) and Tmax/2 (time of reaching extreme value/2) can be used as diagnostic and differential diagnostic indicators for Synucleinopathies.

Conditions
RT-QuIC
Keywords
PD, MSA, PSP, Neurodegeneration disease, alpha-synuclein
Medical subject headings
Thyroid Dyshormonogenesis 2A, Parkinson Disease 4, Autosomal Dominant Lewy Body

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT07498686
Study groupRoleWhat they receive
ControlControl: healthy subjects,
PDparkinson's disease patients
MSAMSA: multiple system atrophy
PSPprogressive supranuclear palsy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. slope

    slope of all Fluorescence value

    Measured: From enrollment to the end of treatment at 21 weeks

  2. MAX

    Maximum fluorescence value

    Measured: From enrollment to the end of treatment at 21 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Mar 2026
  2. Study start1 May 2023
  3. Primary completion15 Nov 2026 (estimated)
  4. Study completion23 Dec 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
458 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07498686
Sponsor's protocol ID
115
Status last verified
Mar 2026
First submitted
23 Mar 2026
Last updated
27 Mar 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of RT-QuIC, run by Xuanwu Hospital, Beijing at 2 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 27 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Weiwei YANG, Ph.D. (+86 010-83198271, yangww_2010@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

slope (time frame: From enrollment to the end of treatment at 21 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in